Advertisement
Two Cleveland Clinic experts will co-direct an upcoming ASH Satellite Symposium preceding the 59th ASH Annual Meeting. Join Hetty Carraway, MD, and Sudipto Mukherjee, MD, MPH, both staff in the Department of Hematology and Medical Oncology, for an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
On the afternoon of December 8, faculty from Cleveland Clinic Cancer Center and other top cancer centers around the world will present an exploration of “A Brave New World: The Clinical Management of Bone Marrow Failure and Myeloid Malignancy in a Time of Personalized Therapy.”
“We are honored to be joined by such distinguished faculty from around the world,” says Dr. Carraway. Faculty include:
This half-day symposium will enable you to identify the role of targeted therapies in myeloid malignancies, describe the impact of checkpoint inhibitors for the treatment of MDS/AML, describe the genomic mutations in MPNs and their impact on pathogenesis and treatment options and more.
For a full agenda and to register, visit the program site.
This activity has been approved for AMA PRA Category 1 credit™.
Advertisement
Advertisement
Oral anticoagulants may be beneficial but need to be balanced against bleeding risks
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival